Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20262310 | 1.00 | MAPK14 (0.37) | MAPK14ITGA4ITGB7CYP4F2CYP4A11 | |
| SCHEMBL28847399 | 0.89 | MAPK14 (0.35) | MAPK14ITGA4ITGB7GSK3BDYRK1A | |
| SCHEMBL6133365 | 0.81 | BRD9 (0.35) | MAPK14ITGA4ITGB7GSK3BDYRK1A | |
| SCHEMBL6133366 | 0.81 | BRD9 (0.35) | MAPK14ITGA4ITGB7GSK3BDYRK1A | |
| SCHEMBL6133253 | 0.80 | MAPK14 (0.40) | MAPK14ITGA4ITGB7GSK3BDYRK1A | |
| SCHEMBL20262324 | 0.78 | MAPK14 (0.35) | MAPK14CYP4F2CYP4A11GSK3BDYRK1A | |
| SCHEMBL20262326 | 0.78 | MAPK14 (0.35) | MAPK14CYP4F2CYP4A11GSK3BDYRK1A | |
| SCHEMBL20262397 | 0.74 | ITGA4 (0.36) | MAPK14ITGA4ITGB7GSK3BDYRK1A | |
| SCHEMBL2173526 | 0.73 | MAPK1 (0.41) | MAPK14GSK3BDYRK1ACNR2IDO1 | |
| SCHEMBL24255779 | 0.72 | GSK3B (0.37) | MAPK14ITGA4ITGB7GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4095138-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| EP-3555093-B1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | disclosed |
| CN-110072863-B | RIP1 kinase inhibitors and methods of use | 豪夫迈·罗氏有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3555093-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109097-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | RIPK1, RIPK2, RIPK4 | MAPK14 438/4885ITGA4 4766/4885ITGB7 4262/4885 |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | MAPK14 438/4885ITGA4 4766/4885ITGB7 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.